Bernard H. Bochner
A5086957919- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Epigenetics and DNA Methylation
- Esophageal Cancer Research and Treatment
- Renal cell carcinoma treatment
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Prostate Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Ureteral procedures and complications
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Colorectal Cancer Screening and Detection
- Prostate Cancer Treatment and Research
- Metastasis and carcinoma case studies
- Urinary Bladder and Prostate Research
- Colorectal Cancer Surgical Treatments
- Infectious Disease Case Reports and Treatments
- Immune Cell Function and Interaction
- Fibroblast Growth Factor Research
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2011-2025
Cornell University
2013-2023
University of Southern California
1995-2023
USC Norris Comprehensive Cancer Center
1995-2023
New York Proton Center
2012-2022
Weill Cornell Medicine
2021
The Ohio State University
2020
Molecular Oncology (United States)
2020
Mount Sinai Hospital
2018
PURPOSE: To evaluate our long-term experience with patients treated uniformly radical cystectomy and pelvic lymph node dissection for invasive bladder cancer to describe the association of primary tumor stage regional status clinical outcomes. PATIENTS AND METHODS: All undergoing bilateral iliac lymphadenectomy, intent cure, transitional-cell carcinoma between July 1971 December 1997, or without adjuvant radiation chemotherapy, were evaluated. The course, pathologic characteristics, outcomes...
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment disease. As part The Cancer Genome Atlas project, we report here an integrated analysis 131 urothelial carcinomas to provide comprehensive landscape molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved cell-cycle regulation,...
This multidisciplinary, evidence-based guideline for clinically non-metastatic muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of guided toward curative intent.A systematic review utilizing research from Agency Healthcare Research Quality as well additional supplementation by authors consultant methodologists was used to develop guideline. Evidence-based statements were based body evidence strengths Grade A, B or C designated Strong, Moderate Conditional...
Cancer drugs often induce dramatic responses in a small minority of patients. We used whole-genome sequencing to investigate the genetic basis durable remission metastatic bladder cancer patient treated with everolimus, drug that inhibits mTOR (mammalian target rapamycin) signaling pathway. Among somatic mutations was loss-of-function mutation TSC1 (tuberous sclerosis complex 1), regulator pathway activation. Targeted revealed about 8% 109 additional cancers examined, and correlated...
We postulate that the number of lymph nodes examined in cystectomy specimens can have an impact on outcome patients with bladder cancer.We analyzed data 322 muscle invasive cancer who underwent radical and bilateral pelvic lymphadenectomy. evaluated associations identified by pathologist surgical specimen local recurrence rate survival outcome.Patients were divided into groups node status distribution examined. In stages pN0 pN+ cases improved was associated a greater determined at least 9...
Cisplatin-based chemotherapy is the standard of care for patients with muscle-invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based associated improved survival, although molecular determinants cisplatin response are incompletely understood. We performed whole-exome sequencing on pretreatment tumor and germline DNA from 50 carcinoma who received followed by cystectomy (25 "responders," 25 pT2+ "nonresponders") identify somatic mutations that...
Radical cystectomy and pelvic lymphadenectomy (PLND) remains the standard treatment for localized regionally advanced invasive bladder cancers. We have constructed an international cancer database from centers of excellence in management consisting patients treated with radical PLND. The goal this study was development a prognostic outcomes nomogram to predict 5-year disease recurrence risk after cystectomy.Institutional databases containing detailed information on were obtained 12...
Tumor stage, histologic grade, and regional lymph node status are currently used to obtain prognostic information about bladder cancers. However, additional indicators needed aid clinicians in selecting patients who would benefit most from specific therapies. A majority of studies assessing the value measuring tumor angiogenesis (i.e., measurement microvessel densities) have found a positive association between increasing densities worsening prognosis.We explored relationship established...
Perioperative cisplatin-based chemotherapy has shown benefit in patients with high-risk localized urothelial bladder cancer, but it is not widely used. Renal impairment may be a major factor limiting its use. The current study was designed to determine the proportion of ineligible receive adjuvant based on inadequate renal function alone.Patients who underwent radical cystectomy for cancer evidence extravesical disease (> or =pT3 any N+) were identified. Patients received neoadjuvant...
Abstract BACKGROUND. By using the age‐adjusted Charlson comorbidity index (ACCI), authors characterized impact of age and on disease progression overall survival after radical cystectomy (RC) for transitional cell carcinoma bladder. Also evaluated was whether ACCI associated with clinicopathologic treatment characteristics. METHODS. The 1121 patients treated by RC bladder at a single institution (1990–2004). Logistic regression used to determine relation between clinical features. They...
Purpose We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer serve as a platform for therapeutic drug discovery. Patients Methods An integrative analysis 97 tumors was conducted identify targets, which are defined that have been clinically validated another type (eg, BRAF mutation) or selective inhibitor target pathway is under clinical investigation. DNA copy number (CNAs) were by using array comparative...
Purpose: Platinum-based chemotherapy remains the standard treatment for advanced urothelial carcinoma by inducing DNA damage. We hypothesize that somatic alterations in damage response and repair (DDR) genes are associated with improved sensitivity to platinum-based chemotherapy.Experimental Design: Patients diagnosis of locally metastatic treated who had exon sequencing Memorial Sloan Kettering-Integrated Mutation Profiling Actionable Cancer Targets (MSK-IMPACT) assay were identified....
To evaluate our long-term experience with patients treated uniformly radical cystectomy and pelvic lymph node dissection for invasive bladder cancer to describe the association of primary tumor stage regional status clinical outcomes.